ClinicalTrials.gg
CompletedNCT05338099Updated Aug 30, 2024

Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)

A Phase 1 interventional study of EN001 and EN001 in Duchenne Muscular Dystrophy, sponsored by ENCell. Completed at 1 site in Korea, Republic of. Open to male participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-08-30.

Sponsored by ENCell · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
2 Years to 18 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Muscular Dystrophy, Duchenne with a site in Korea, Republic of — 3 open to participants now, 9 under way, 3 of them phase 3. Muscular Dystrophy, Duchenne · Korea, Republic of.

Enrollment
20th of 20
7 · median 106
Started
2022
with 1 other
Phase 1
2 of 23
none open now
Registered
15th of 23
by date
Lead sponsor
2 of 23
ENCell

Among the 23 studies in Muscular Dystrophy, Duchenne with a site in Korea, Republic of, this one is the 20th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 1, and was the 15th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

3 of the 23 studies in Muscular Dystrophy, Duchenne with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 18 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Muscular Dystrophy, Duchenne with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients with Duchenne Muscular Dystrophy(DMD)

Read the detailed description

It is the first in human (FIH), 3+3 design clinical trial to evaluate the safety and tolerability and determine the maximum tolerated dose (MTD) of EN001 (allogeneic umbilical cord-derived mesenchymal stem cells) in the treatment of Duchenne Muscular Dystrophy (DMD).

03

Conditions studied

  • Duchenne Muscular Dystrophy
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Those aged 2 to 18 years old
  2. Male
  3. Those who are diagnosed with DMD due to a mutation in the dystrophin gene identified by a genetic test
  4. Phenotypic evidence of DMD

    • Clinical signs or symptoms (proximal weakness, waddling gait, Gowers maneuver)
    • Elevated serum creatine kinase level
  5. Those who have been using systemic at a stable dose for 24 weeks prior to screening and are expected to maintain the constant dose throughout the study period
  6. Those who agree to use effective measures until the short-term follow-up period of the clinical trial. In addition, their partner must also use a medically acceptable method of contraception (ie, oral contraceptives for women) for the same period.
  7. Those who are willing to agree with the ICF and whose parent or representative is willing to provide written consent for the subject's participation in the clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Those who have clinical signs or symptoms of cardiomyopathy, defined as \<50% on echocardiography at screening
  2. If ventilatory support is required during the day or if invasive mechanical ventilation via tracheostomy is used (Non-invasive ventilation such as positive pressure ventilation is allowed at night)
  3. If core antibody and antibody are positive
  4. If there is a history of major surgery within 12 weeks or it is expected during the study period
  5. Those who have been exposed to gene therapy or genome editing within 24 weeks from the screening
  6. Those who have experience with stem cell therapy
  7. Those who have been administered Translarna granules (Ataluren) within 24 weeks from the screening
  8. Those who are receiving treatment (other than ) that may affect muscle strength or function within 12 weeks prior to screening
  9. If laboratory test values are abnormal at the time of screening

    • \<10 g/dL
    • Serum albumin \<2.5 g/dL
    • count \<50,000/ml
    • Abnormal GGT or total (>laboratory's )
    • Abnormal renal function (Serum creatinine >1.5 Times laboratory's upper limit of normal)"
  10. Those with significant neuromuscular or genetic diseases other than DMD
  11. Those with significant heart, lung, liver, kidney, hematological, immunological, behavioral disease, or other diseases including malignant tumors
  12. Those who have a previous or current medical condition that may adversely affect the safety of the subject, make it difficult to complete treatment, or affect the evaluation of clinical trial results at the discretion of the investigator
  13. Those who do not have the will or ability to comply with clinical trial procedures at the discretion of the investigator
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Dose group A (Low dose)

    Participants will receive EN001 intravenously (IV) once on Day 1. Before 30 minutes EN001 dosing, there will be premedication (solu-cortef 1-2 mg/kg + Lorazepam 0.1 mg/kg (max 2 mg) + Ondansetron (5 mg/m\^2) + Chlorpheniramine (1 mg for 2\~6 years old; 2 mg for 6\~12 years old; 4 mg for over 12 years old)+ Acetaminophen) administered to assure safety of participants from issues such as immune rejection, due to the process of thawing in a frozen state of EN001.

    Drug: EN001

  • Experimental
    Dose group B (High dose)

    Participants will receive EN001 intravenously (IV) once on Day 1. Before 30 minutes EN001 dosing, there will be premedication (solu-cortef 1-2 mg/kg + Lorazepam 0.1 mg/kg (max 2 mg) + Ondansetron (5 mg/m\^2) + Chlorpheniramine (1 mg for 2\~6 years old; 2 mg for 6\~12 years old; 4 mg for over 12 years old)+ Acetaminophen) administered to assure safety of participants from issues such as immune rejection, due to the process of thawing in a frozen state of EN001.

    Drug: EN001

Interventions

  • DrugEN001

    EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows. Dose group A (Low dose): 5.0x10\^5 cells/kg

    Also known as: EN001 (Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells)

  • DrugEN001

    EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows. Dose group B (High dose): 2.5x10\^6 cells/kg

    Also known as: EN001 (Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells)

06

What researchers measure

Primary outcomes

  1. Number of participants of any Adverse Events (AEs)/Serious Adverse Events (SAEs) related investigational product

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: Week 12 after treatment

  2. Determination of Dose-limiting toxicity (DLT) levels of EN001

    Among the adverse events occurring for 2 weeks after administration of the investigational product, Grade 3 or higher adverse events according to CTCAE 5.0

    Time frame: Up to Week 2 after dosing on Day 0

  3. Determination of Maximum tolerated dose (MTD) levels of EN001

    Among the adverse events occurring for 2 weeks after administration of the investigational product, Grade 3 or higher adverse events according to CTCAE 5.0 Maximum tolerated dose defines the evaluated maximum dose level in which greater than two participants of six participants experience Dose-limiting toxicity (DLT) under the dose level. The dose level where two participants of six participants experience DLT will be the maximum tolerated dose.

    Time frame: Up to Week 2 after dosing on Day 0

  4. Number of participants with Vital Signs abnormalities

    Vital Signs include blood pressure (mmHg), pulse (times/minute), respiratory rate (times/minute), and body temperature (℃) and will be assessed by CTCAE v 5.0 to evaluate safety and tolerability of EN001. The number of participants with at least one potentially clinically significant abnormal vital sign finding were reported as treatment emergent adverse events (TEAEs).

    Time frame: Week 12 after screening

  5. Number of participants with clinically significant abnormalities of Physical Examinations

    Physical Examinations include general appearance, head, ears/eyes/nose/throat, cardiovascular, respiratory, abdomen, skin, lymph nodes, extremities, musculoskeletal and neurologic and will be assessed by CTCAE v 5.0 to evaluate safety and tolerability of EN001. Number of participants with potentially clinically significant abnormalities in physical examinations were reported as TEAEs.

    Time frame: From screening up to Week 12

  6. Number of participants with abnormalities of Laboratory Parameters

    Laboratory Parameters include hematology, chemistry laboratory tests, urinalysis, coagulation test and plasma viral load test and will be assessed by CTCAE 5.0 to evaluate safety and tolerability of EN001. Number of participants with at least one potentially clinically significant abnormal finding were reported as TEAEs.

    Time frame: From screening up to Week 12

  7. Number of participants with abnormalities of 12-lead Electrocardiography (ECG)

    Categorical summarization ECG criteria were as follows: 1. QT interval, QTcB, QTcF and QTcP: increase from baseline \>30 millisecond \[ms\] or 60 ms; absolute value \> 450 ms, \>480 ms, and \> 500 ms; 2. heart rate (HR): change from baseline ≥20 beats per minute \[bpm\] and absolute value≤50 bpm or ≥120 bpm; 3. PR interval: absolute value ≥220 ms and increase from baseline≥20 ms; 4. QRS: ≥120 ms.

    Time frame: From screening to baseline on Day 0 (Predose to end of infusion and 90 min after completion of infusion)

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Occurrence of any adverse reactions, development of new blood clots, tumors, immune responses (like autoimmune reactions) and death, and/or serious adverse events related investigational product will be summarized by actual treatment groups respectively.

    Time frame: From screening to the end of treatment/withdrawal visit (up to approximately 5 years per subject)

  2. Number of participants with abnormalities of Vital Signs, Physical Findings, and Laboratory Parameters

    Abnormalities of Vital Signs, Physical Findings, and Laboratory parameters (as described above) will be collected and analyzed, and then assessed by CTCAE 5.0 to evaluate the long-term safety of EN001.

    Time frame: From screening to the end of treatment/withdrawal visit (up to approximately 5 years per subject)

  3. Rate of change at the time of visit compared to baseline (percent [%]) in CK level

    Creatinine kinase (CK) level will be collected and analyzed to evaluate the exploratory efficacy of EN001. - CK level(%) = (CK level after dosing - CK level in baseline)/(CK level in baseline)\*100

    Time frame: From screening up to the end of support (up to approximately 5 years per subject at each visit)

  4. Change from baseline in Function tests

    Function tests measured by North Star Ambulatory Assessment (NSAA), Six Minute Walk Test (6MWT), Myometry. and Lung capacity (and only K-Cross Motor Function Measure (KGMFM) will be performed under 5 years old) will be collected and analyzed to evaluate the exploratory efficacy of EN001. - Function tests = value in visit - value in baseline

    Time frame: Screening and baseline on Day -1 (up to approximately 5 years per subject after Week 12)

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Dec 2022, 11 months.

Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2022
First posted
Apr 20, 2022
StartActual
Jan 18, 2022
Primary completionActual
Dec 28, 2022
CompletionActual
Dec 28, 2022
Last update
Aug 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05338099
Lead sponsor
ENCell
Responsible party
Sponsor
First posted
Apr 20, 2022
Start date
Jan 18, 2022
Primary completion
Dec 28, 2022
Completion
Dec 28, 2022
Last update
Aug 30, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EN001

Start the discussion